Publications

5677 Results

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

Authors
F Andre;N Ismaila;K Allison;W Barlow;D Collyar;S Damodaran;NL Henry;K Jhaveri;K Kalinsky;N Kuderer;A Litvak;E Mayer;L Pusztai;R Raab;A Wolff;V Stearns
Journal / Conference
Journal of Clinical Oncology Jun 1;40(16):1816-1837
Year
2022
Research Committee(s)
Breast

SWOG/NRG S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab + SBRT versus SBRT Alone in High Risk, Early-Stage NSCLC (NCT#04214262)

Authors
M Daly;M Redman;C Simone;A Monjazeb;J Bauman;P Hesketh;J Feliciano;R Kashani;C Steuer;A Ganti;J Miao;J Moon;C Hu;J Bradley;K Kelly
Journal / Conference
International Journal of Radiation Biology Physics VOLUME 114, ISSUE 3, SUPPLEMENT, E414, NOVEMBER 01, 2022;ASTRO Annual Meeting (October 23 - 26, 2022, San Antonio, TX), TIP poster
Year
2022
Research Committee(s)
Lung
Study Number(s)
S1914

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up

Authors
T Flaig;C Tangen;S Daneshmand;A Alva;M Lucia;D McConkey;D Theodorescu;A Goldkorn;M Milowsky;R Bangs;G MacVicar;B Bastos;J Fowles;D Gustafson;M Plets;IM Thompson;SP Lerner
Journal / Conference
J Clin Oncol 40, 2022 (suppl 6; abstr 536); ASCO Genitourinary (GU) Cancers Symposium 2022 (Feb 17-19, 2022, San Francisco, CA), poster
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
S1314

Effects of a guideline-informed clinical decision support system intervention to improve colony stimulating factor prescribing: A Pragmatic Cluster-Randomized Trial

Authors
S Ramsey;S Bansal;S Sullivan;G Lyman;W Barlow;K Arnold;K Watabayashi;A Bell-Brown;K Kreizenbeck;N Le-Lindqwister;C Dul;U Brown-Glaberman;R Behrens;V Vogel;N Alluri;D Hershman
Journal / Conference
JAMA Network Open Oct 3;5(10):e2238191
Year
2022
Research Committee(s)
Cancer Care Delivery
PMID
PMID36279134
PMC
PMC9593234
Study Number(s)
S1415CD

Accommodating population differences when validating risk prediction models

Authors
R Pfeiffer;Y Chen;M Gail;D Ankerst
Journal / Conference
Statistics in Medicine 2022 Oct 30;41(24):4756-4780. doi: 10.1002/sim.9447. Epub 2022 Jul 5
Year
2022
Research Committee(s)
Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
PMID
PMID36224712
Study Number(s)
S0000

Trends in Obesity Prevalence Among Patients Enrolled in Clinical Trials for Obesity-Related Cancers, 1986 to 2016

Authors
R Vaidya;C Till;H Greenlee;D Hershman;J Unger
Journal / Conference
JAMA Network Open 2022 Oct 3;5(10):e2234445
Year
2022
Research Committee(s)
Cancer Care Delivery and Multiple sites
PMID
PMID36215073
PMC
PMC9552895

An Evaluation of Stakeholder Engagement in Comparative Effectiveness Research: Lessons Learned from SWOG S1415CD

Authors
A Bell-Brown;K Watabayashi;K Kreizenbeck;S Ramsey;A Bansal;W Barlow;G Lyman;DL Hershman;A Mercurio;B Segarra-Vazquez;F Kurttila;J Myers;J Golenski;J Johnson;R Erwin;S Sullivan
Journal / Conference
Journal of Comparative Effectiveness Research Dec;11(18):1313-1321
Year
2022
Research Committee(s)
Cancer Care Delivery
PMID
PMID36378570
PMC
PMC9832319
Study Number(s)
S1415CD

Differential Biopsy Patterns Influence Associations Between Multivitamin Use and Prostate Cancer Risk in the Selenium and Vitamin E Cancer Prevention Trial

Authors
J Schenk;C Till;M Neuhouser;P Goodman;MS Lucia;IM Thompson;C Tangen
Journal / Conference
Cancer Epidemiology Biomarkers & Prevention Nov 2;31(11):2063-2069
Year
2022
Research Committee(s)
Prevention, Screening, and and Surveillance
PMID
PMID36084322
PMC
PMC9756313
Study Number(s)
S0000

Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations

Authors
P Brastianos;E Twohy;E Gerstner;T Kaufmann;A Iafrate;S Jeyapalan;D Piccioni;V Monga;A Lassman;C Fadul;D Schiff;J Taylor;S Chowdhary;C Bettegowda;G Ansstas;F Lieberman;M De La Fuente;R Peterson;S Anderson;M Anderson;N Shonka;D Damek;L Kunschner-Ronan;R Chaurhary;M O'Rourke;F Senecal;J Carrillo;T Kaley;T Morrison;A Thomas;M Welch;F Iwamoto;D Cachia;A Cohen;S Vora;M Knopp;I Dunn;P Kumthekar;J Sarkaria;S Geyer;X Carrero;M Martinez-Lage;D Cahill;P Brown;C Giannini;S Santagata;F Barker;E Galanis
Journal / Conference
Journal of Clinical Oncology Oct 26;JCO2102371. doi: 10.1200/JCO.21.02371. Online ahead of print.
Year
2022
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID36288512
Study Number(s)
CTSU/A071401

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial

Authors
M Katz;Q Shi;J Meyers;J Herman;M Chuong;B Wolpin;S Ahmad;R Marsh;L Schwartz;S Behr;W Frankel;E Collisson;J Leenstra;T Williams;G Vaccaro;A Venook;J Meyerhardt;E O'Reilly
Journal / Conference
JAMA Oncology Sep 1;8(9):1263-1270. doi: 10.1001/jamaoncol.2022.2319
Year
2022
Research Committee(s)
Gastrointestinal
PMID
PMID35834226
PMC
PMC9284408
Study Number(s)
CTSU/A021501